Company: Nexstim Plc

Transaction: Directed issue

Issue volume: 31.0 MSEK

Date: November 2019

Nexstim is a globally operating medical technology company that offers personalised and effective therapies and diagnostics for challenging brain diseases and disorders.

The company has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. The technology is used in Nexstim’s proprietary Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.

The proceeds of the directed issue will be used for marketing and similar commercialisation efforts particularly in the US market, financing the company’s purchases regarding NBT® system deliveries, repayment of loans, evaluating new clinical trials in the area of chronic neuropathic pain as well as financing the company’s R&D and working capital needs.

Augment acted as financial advisor to Nexstim in the directed issue.